The EDC is live today — see what ships now
All studies
NCT07288320From ClinicalTrials.govRecruiting

An Assessment of Efficacy, Safety, and Pharmacokinetics of NBI-1117568 in Adults With Bipolar I Disorder With Current Mania

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Pharmacokinetics of NBI-1117568 in Adults With Bipolar I Disorder Who Are Currently Experiencing a Manic Episode or Manic Episode With Mixed Features, With or Without Psychotic Symptoms, and Warrant Inpatient Hospitalization

  • Bipolar I Disorder
  • Mania

At a glance

Phase
Phase 2
Study type
Interventional
Sponsor
Neurocrine Biosciences
Enrolment target
150
Started
24 December 2025
Main results due
February 2028
Study sites
11
Registry updated
29 September 2026

Can you take part?

  • Ages 18 years to 65 years.
  • Open to any sex.
  • You need the condition being studied — healthy volunteers are not accepted.

These are the headline rules only. Every study has a longer list, and whether you are eligible is decided by the research team at the site — never by this page.

Read the full eligibility criteria
Key Inclusion Criteria:

* Participant has a primary diagnosis of bipolar I disorder.
* The participant has had at least 1 prior documented manic episode that required treatment.
* The participant is experiencing an acute manic episode or manic episode with mixed features, with or without psychotic symptoms.

Key Exclusion Criteria:

* Any unstable or poorly controlled medical condition or chronic disease (including history of neurological, hepatic, renal, cardiovascular, gastrointestinal, pulmonary, autoimmune, or endocrine disease that may affect study participation or results), or malignancy within 90 days before the start of screening.
* Primary diagnosis is not bipolar I disorder.
* History of clozapine treatment for treatment-resistant psychosis.
* History of psychiatric hospitalization(s) for ≥30 consecutive days during the 90 days before the start of screening.

Note: Additional inclusion/exclusion criteria may apply, per protocol.

What this study is about

In the sponsor’s own words, from the registry.

The primary objective for this study is to evaluate the efficacy of NBI-1117568 compared with placebo on improving manic symptoms in adults with bipolar I disorder who are currently experiencing an episode of mania with or without mixed features.

Study sites(11)

  • Neurocrine Clinical Site

    Little Rock, Arkansas, United States

    Recruiting

  • Neurocrine Clinical Site

    Cerritos, California, United States

    Recruiting

  • Neurocrine Clinical Site

    Garden Grove, California, United States

    Recruiting

  • Neurocrine Clinical Site

    San Diego, California, United States

    Recruiting

  • Neurocrine Clinical Site

    Hollywood, Florida, United States

    Recruiting

  • Neurocrine Clinical Site

    Atlanta, Georgia, United States

    Recruiting

  • Neurocrine Clinical Site

    Gaithersburg, Maryland, United States

    Recruiting

  • Neurocrine Clinical Site

    Marlton, New Jersey, United States

    Recruiting

  • Neurocrine Clinical Site

    Staten Island, New York, United States

    Recruiting

  • Neurocrine Clinical Site

    Austin, Texas, United States

    Recruiting

  • Neurocrine Clinical Site

    Houston, Texas, United States

    Recruiting

Showing 11 of 11 sites. 11 of the 11 sites on this study are recruiting right now — a site can stop enrolling while the study as a whole is still open.

Source: ClinicalTrials.gov record NCT07288320. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.

Not the right study?

Answer three questions and see the studies recruiting near you, in plain language.

Find a study for me
An Assessment of Efficacy, Safety, and Pharmacokinetics of NBI-1117568 in Adults With Bipolar I Disorder With | Trialion